Intracellular signalings underlying bradykinin-induced matrix metalloproteinase-9 expression in rat brain astrocyte-1

被引:65
作者
Hsieh, HL
Yen, MH
Jou, MJ
Yang, CM
机构
[1] Chang Gung Univ, Dept Physiol & Pharmacol, Tao Yuan, Taiwan
[2] Grad Inst Life Sci, Natl Def Med Ctr, Taipei, Taiwan
[3] Natl Def Med Ctr, Dept Pharmacol, Taipei, Taiwan
关键词
bradykinin; astrocytes; matrix metalloprotease-9; p42/p44 mitogen-activated protein kinase; protein kinase B/Akt;
D O I
10.1016/j.cellsig.2004.03.021
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Bradykinin (BK), an inflammatory mediator, has been shown to increase the expression of proteins such as matrix metalloproteinases (MMPs) on brain cells and contributes to the pathophysiology of inflammatory responses. However, the mechanisms regulating MMP-9 expression by BK in rat brain astrocytes-1 (RBA-1) remain unclear. Here we report that the mitogen-activated protein kinase (MAPK) and NF-kappaB pathways participate in the induction of MMP-9 expression induced by BK in RBA cells. Zymographic, Western blotting, and RTPCR analyses showed that BK increased expression of MMP-9 mRNA and protein in a time- and concentration-dependent manner. BK-induced MMP-9 mRNA and protein expression was inhibited by MEK1/2 inhibitor PD98059, PI3-K inhibitor LY294002, and NF-kappaB inhibitor helenalin. In accordance with these findings, BK-induced phosphorylation of p42/p44 MAPK and Akt and activation of NF-kappaB was attenuated by prior treatment with PD98059, LY294002, and helenalin, respectively. The effects of BK on MMP-9 expression and p42/p44 MAPK and Akt phosphorylation were inhibited by B-2 receptor antagonist Hoe 140, indicating the involvement of B-2 receptors revealed by [H-3]-BK binding assay. Furthermore, BK-stimulated translocation of NF-kappaB into the nucleus was revealed by Western blotting and immnofluorescence staining and blocked by Hoe 140, PD98059, LY294002, and helenalin. Taken together, these results suggest that in RBA cells, activation of p42/p44 MAPK and Akt cascades mediated through NF-kappaB pathway are essential for BK-induced MMP-9 gene expression. This study may provide insights into the regulation of MMP-9 production in CNS, which may occur in vivo in pathological situations such as CNS inflammation and brain astrocytoma. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1163 / 1176
页数:14
相关论文
共 70 条
[1]   Blood-brain barrier disruption and matrix metalloproteinase-9 expression during, reperfusion injury - Mechanical versus embolic focal ischemia in spontaneously hypertensive rats [J].
Aoki, T ;
Sumii, T ;
Mori, T ;
Wang, XY ;
Lo, EH .
STROKE, 2002, 33 (11) :2711-2717
[2]   Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes [J].
Arai, K ;
Lee, SR ;
Lo, EH .
GLIA, 2003, 43 (03) :254-264
[3]   Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia [J].
Asahi, M ;
Wang, XY ;
Mori, T ;
Sumii, T ;
Jung, JC ;
Moskowitz, MA ;
Fini, ME ;
Lo, EH .
JOURNAL OF NEUROSCIENCE, 2001, 21 (19) :7724-7732
[4]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[5]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   Ten years of protein kinase B signalling: a hard Akt to follow [J].
Brazil, DP ;
Hemmings, BA .
TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (11) :657-664
[8]  
CHEN CC, 1995, MOL PHARMACOL, V48, P39
[9]   Bradykinin-stimulated p42/p44 MAPK activation associated with cell proliferation in corneal keratocytes [J].
Cheng, CY ;
Huang, SCM ;
Hsiao, LD ;
Sun, CC ;
Jou, MJ ;
Yang, CM .
CELLULAR SIGNALLING, 2004, 16 (05) :535-549
[10]   Nuclear factor κB:: a pivotal role in the systemic inflammatory response syndrome and new target for therapy [J].
Christman, JW ;
Lancaster, LH ;
Blackwell, TS .
INTENSIVE CARE MEDICINE, 1998, 24 (11) :1131-1138